Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Gemcitabine plus erlotinib in unresectable pancreatic cancer
jRCT2080220332Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of erlotinib in pancreatic cancer (PC) and pancreatic adenosquamous carcinoma (PASC), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCT2080220332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220332.